Linking Neurology And Ophthalmology For Clinical Trials

20/20 Onsite is recognized by the FDA for its innovative approach to integrating ophthalmology with neurology and central nervous system (CNS) research. The company is using ophthalmic assessments for early detection of neurological disorders, non-invasive CNS monitoring, and enhanced safety protocols. As the link between ocular health and CNS conditions like Alzheimer's and Multiple Sclerosis becomes clearer, biopharmaceutical companies are increasingly incorporating these insights into their clinical trial designs. 20/20 Onsite's advanced mobile vision clinics and patient-centric methodologies ensure high-quality, accessible data collection, improving trial outcomes and patient involvement. However, integrating ocular endpoints in neurology trials presents challenges, particularly in recruiting principal investigators (PIs) with suitable patient populations willing to participate. In this article, we explore these challenges and present a possible solution.